PE-Backed WuXi Biologics’ $510M Hong Kong IPO Cheered By Investors

WuXi Biologics (Cayman) Inc., a Chinese contract drug manufacturer whose parent company is controlled by a group of leading private equity firms, has seen its share price soar after completing a HK$3.98 billion (US$510 million) initial public offering on the Kong Exchange Stock Exchange.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in